Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Sep 22, 2026 · Filed Sep 22, 2026
Cytokinetics's Research & Development sold $239K of Cytokinetics shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$239,015
Shares × reported transaction price
47 days after results of Aug 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $67.59 on Sep 22, 2026, 23% above its 52-week low and 23% below its high, after a 13% drop over the previous 30 trading days
52-week range $54.76 (Oct 22, 2025) to $87.26 (Jun 29, 2026), 39% of the way up, from 242 adjusted closes. 30 trading days earlier: $77.49 on Aug 10, 2026. Describes the past only, not a forecast
Filing box checked: sold under a Rule 10b5-1 plan
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.1% | −0.7% | +0.8% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Officer sold ~$215K of Cytokinetics
Automatic saleDerivative exercise or conversion — not an open-market buy.